Get the Stockscreener App
3.15
30.84%
-1.39
Collplant Biotechnologies Ltd stock is traded at $3.15, with a volume of 293.57K.
It is down -30.84% in the last 24 hours and up +48.11% over the past month.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
See More
Previous Close:
$4.54
Open:
$3.6
24h Volume:
293.57K
Relative Volume:
5.06
Market Cap:
$36.08M
Revenue:
$10.96M
Net Income/Loss:
$-7.02M
P/E Ratio:
-4.9219
EPS:
-0.64
Net Cash Flow:
$-3.72M
1W Performance:
+62.69%
1M Performance:
+48.11%
6M Performance:
-29.91%
1Y Performance:
-42.91%
1-Day Range:
$3.00
$3.855
1-Week Range:
$1.93
$4.98
52-Week Range:
$1.55
$5.61
Collplant Biotechnologies Ltd Stock (CLGN) Company Profile
Name
Collplant Biotechnologies Ltd
Sector
Industry
Phone
-
Address
-
Compare CLGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLGN
Collplant Biotechnologies Ltd
|
3.1485 | 23.02M | 10.96M | -7.02M | -3.72M | -0.64 |
|
ONC
Beone Medicines Ltd Adr
|
246.52 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.96 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.76 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.63 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Collplant Biotechnologies Ltd Stock (CLGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-23 | Initiated | Alliance Global Partners | Buy |
Collplant Biotechnologies Ltd Stock (CLGN) Latest News
CollPlant Biotechnologies (CLGN) Rating and Price Target Analysis | CLGN Stock News - GuruFocus
CollPlant (CLGN) Announces $3.6M Direct Offering and Private Placement - GuruFocus
CollPlant Biotechnologies shares slide after announces capital raise of $3.6M through registered direct offering - MSN
CollPlant (CLGN) Announces New Share and Warrant Sale Agreement - GuruFocus
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRE - GuruFocus
CollPlant announces $3.6 million stock offering By Investing.com - Investing.com India
CollPlant announces $3.6 million stock offering - Investing.com Australia
CollPlant Raises $3.6M to Advance AbbVie Partnership and Breakthrough Regenerative Medicine Programs - Stock Titan
CollPlant Biotechnologies (NASDAQ:CLGN) Price Target Lowered to $12.00 at D. Boral Capital - Defense World
CollPlant Biotechnologies Reports Strong Q1 2025 Results - TipRanks
Collplant Biotechnologies Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
CollPlant Biotechnologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
CollPlant Biotechnologies (CLGN) Analyst Ratings Update | CLGN S - GuruFocus
CollPlant Biotechnologies (CLGN) Analyst Ratings Update | CLGN Stock News - GuruFocus
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL R - GuruFocus
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE | CLGN Stock News - GuruFocus
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE - Nasdaq
CollPlant Biotechnologies (CLGN) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Earnings Preview: CollPlant Biotechnologies - Nasdaq
Global Tissue Engineering Market Insights & Industry Outlook | - openPR.com
When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Breakeven? - simplywall.st
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINAN - GuruFocus
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS - Financial Times
Renaissance Technologies LLC Acquires New Stake in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) - Defense World
Here's Why We're A Bit Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation - Yahoo Finance
CLGNCollplant Biotechnologies Ltd Latest Stock News & Market Updates - Stock Titan
Collplant stock hits 52-week low at $2.14 amid market challenges - Investing.com India
Collplant stock hits 52-week low at $2.14 amid market challenges By Investing.com - Investing.com South Africa
CollPlant's Collink.3D® BioInks and Technologies Offer a Relevan - GuruFocus
FDA Animal Testing Phase-Out: How CollPlant's BioInk Tech Could Revolutionize Drug Safety Studies - Stock Titan
Collplant stock hits 52-week low at $2.47 amid market challenges By Investing.com - Investing.com South Africa
Collplant stock hits 52-week low at $2.47 amid market challenges - Investing.com India
CollPlant Biotechnologies’ (CLGN) Buy Rating Reaffirmed at D. Boral Capital - The AM Reporter
D. Boral Capital Reaffirms “Buy” Rating for CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World
Collplant plans clinical trials for dermal filler and advances regenerative implants - MSN
CollPlant Biotechnologies (CLGN) to Release Earnings on Thursday - Defense World
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q4 2024 Earnings Call Transcript - Insider Monkey
CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highlights: Navigating Revenue ... - Yahoo
CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highl - GuruFocus
CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highlights: Navigating Revenue ... By GuruFocus - Investing.com Canada
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Sees Large Decline in Short Interest - Defense World
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE - StreetInsider.com
Earnings call transcript: Collplant Biotechnologies Q4 2024 misses forecasts - Investing.com India
CollPlant Biotechnologies Reports 2024 Financial Results - TipRanks
CollPlant’s Earnings Call: Mixed Outlook Amid Innovations - TipRanks
SEC Form 20-F filed by CollPlant Biotechnologies Ltd - Quantisnow
Collplant Biotechnologies Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Collplant stock hits 52-week low at $2.9 amid market challenges - Investing.com Australia
Collplant stock hits 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa
What To Expect From CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings - GuruFocus
Collplant Biotechnologies Ltd expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Collplant Biotechnologies Ltd Stock (CLGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):